Maptelligent, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MAPT research report →
Price Chart
About the company
Maptelligent, Inc. delivers a cutting-edge cloud-based geographic platform designed to centralize and process critical data. This platform seamlessly integrates diverse information from sources such as sensors, cameras, alarms, and access control systems, transforming it into clear, actionable intelligence presented on an intuitive map interface.
- CEO
- Joseph A. Cosio-Barron
- IPO
- 2020
- Employees
- 3
- HQ
- Henderson, NV, US
Get TickerSpark's AI analysis on MAPT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $158.53K
- P/E
- 0.04
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.03
- EV/EBITDA
- 0.31
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -55.12%
- ROIC
- 39.29%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-6,350+99.1%
- Op Income
- $-651,000
- Net Income
- $2.18M-97.6%
- EPS
- $0.01-99.2%
- OCF Growth
- +26.8%
- FCF Growth
- +20.7%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 8.96
- RSI (14)
- 24
- Avg Volume
- 319
No earnings-call transcripts are available for MAPT yet.
- Free Float
- 100.0%
- Shares Outstanding
- 792.63M
- Float Shares
- 792.63M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 9, 24 | Corso Glenn | other | 0 |
| Apr 9, 24 | Corso Glenn | other | 0 |
| Apr 9, 24 | Ziccardi Richard Edward | other | 0 |
| Apr 9, 24 | Ziccardi Richard Edward | other | 0 |
| Apr 9, 24 | Cosio-Barron Joseph Anthony | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MAPT coverage
Recent articles, reports, and earnings notes.
No research on MAPT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MAPT report →Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
businesswire.com · Sep 29
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
gurufocus.com · Jul 14
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
businesswire.com · Dec 8
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
businesswire.com · Sep 10
Maptelligent, Inc., is Pleased to Announce it has Entered Into an Agreement With Axim Geospatial
globenewswire.com · Dec 13
Maptelligent is Pleased to Announce Its New Strategic Focus, Implementing the Latest in Location Intelligence Making Indoor Maps More Intelligent
globenewswire.com · Feb 23
Maptelligent, Inc., is Pleased to Announce a Partnership with Michael Quan with the Interactive Tactical Group
globenewswire.com · Nov 2
NSION Technologies & Maptelligent Strategic Partnership
globenewswire.com · Sep 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.